Floatz logo

Nab-Rapamycin

Overgrowth Syndrome And/Or Cerebral Malformations Due To Abnormalities In MTOR Pathway Genes

Sarcoma Oncology Research Center, LLCPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Overgrowth Syndrome And/Or Cerebral Malformations Due To Abnormalities In MTOR Pathway Genes cohort.

Asset / SponsorPhaseRating
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC

Same molecule, other indications

Nab-Rapamycin is also rated in:

neoplasm with perivascular epithelioid cell differentiationDormant
CCC
Indicative ·
52 / 100
View asset →
epithelioid sarcomaDormant
CCC
Indicative ·
52 / 100
View asset →
desmoid tumorDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →